(Reuters) - Eli Lilly (LLY) is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by recording nearly $550 million in "pre-launch inventory ...

Seana Smith and Brad Smith examine several stocks on the move this morning: Pharmaceutical giant Eli Lilly (LLY) is cutting costs for GLP-1 weight-loss drug Zepbound. Keurig Dr Pepper (KDP ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

Eli Lilly and Co. Wednesday announced plans to build four pharmaceutical manufacturing sites in the United States, significantly boosting domestic medicine production and adding around 13,000 ...

A major pharmaceutical company that has invested heavily in North Carolina is planning multiple new factories in the U.S. STORY HIGHLIGHTS Eli Lilly plans $27 billion U.S. expansion, will create ...

Eli Lilly LLY.N plans to spend at least $27 billion to build four new manufacturing plants in the U.S., the drugmaker said at a Washington press conference on Wednesday, as it grapples with the ...